Alejandro Bes (pictured), joins Axmed as its new general counsel, effective today. Alejandro Bes’ career path Bes began his legal career as an associate at Freshfields in Spain. He later transitioned to an in-house role,
Tags :Novartis
Advestra acted as Swiss legal counsel to Novartis, which successfully placed notes in the aggregate principal amount of USD 3.7 billion in four tranches of USD 1 billion 3.800%
Advestra advised Novartis on the issuance of CHF 2.2 billion bonds, placed in five tranches as follows: UBS, BNP Paribas (Suisse) and Deutsche Bank Aktiengesellschaft acted as joint lead managers
Novartis AG, the Swiss multinational pharmaceutical corporation based in Basel, has appointed Alejandro Bes (pictured) as its global head of legal for the Immunology business unit. The lawyer steps into the role as his predecessor,
On October 4, 2023, Novartis successfully executed the spin-off of Sandoz by distributing Sandoz shares as a dividend-in-kind to Novartis shareholders and American Depositary Receipts (ADRs) holders. Sandoz shares are now listed on the SIX Swiss Exchange.
Bär & Karrer partner Daniel Hochstrasser (pictured) has been nominated for election to the Board of Directors of Novartis, a global healthcare company based in Switzerland, which will take place at the Annual General
Novartis announced the appointment of Karen L. Hale (pictured) as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN),
She had already worked for Novartis as legal counsel from 2014 to 2017. She joins the company from Amgen where she was associate Legal Counsel Italy & Greece from July 2017 to January 2021. Verdesca also worked as lawyer for
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that Shannon Thyme Klinger (pictured) will join the Company as Chief Legal Officer, effective June 1, 2021.
Novartis announced that Shannon Thyme Klinger (pictured) Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company. Ms. Klinger will step down
